ARAV has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ARAV has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-04-30), Aravive's share price is $0.0401. Aravive's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Sep. 2023 was $-0.78. Hence, Aravive's Price-to-Free-Cash-Flow Ratio for today is N/A.
The historical rank and industry rank for Aravive's Price-to-Free-Cash-Flow or its related term are showing as below:
Aravive's Free Cash Flow per Share for the three months ended in Sep. 2023 was $-0.13. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was $-0.78.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was -6.70% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 36.40% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was 28.40% per year.
During the past 11 years, Aravive's highest 3-Year average Free Cash Flow per Share Growth Rate was 66.50% per year. The lowest was -21.60% per year. And the median was 30.50% per year.
The historical data trend for Aravive's Price-to-Free-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aravive Annual Data | |||||||||||||||||||||
Trend | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | |||||||||||
Price-to-Free-Cash-Flow | Get a 7-Day Free Trial | - | - | - | - | - |
Aravive Quarterly Data | ||||||||||||||||||||
Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | |
Price-to-Free-Cash-Flow | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, Aravive's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Aravive's Price-to-Free-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Aravive's Price-to-Free-Cash-Flow falls into.
Aravive's Price-to-Free-Cash-Flow ratio for today is calculated as
Price-to-Free-Cash-Flow Ratio | = | Share Price | / | Free Cash Flow per Share (TTM) |
= | 0.0401 | / | -0.778 | |
= | N/A |
Aravive's Share Price of today is $0.0401.
Aravive's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.78.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Price-to-Free-Cash-Flow Ratio | = | Market Cap | / | Free Cash Flow |
Aravive (NAS:ARAV) Price-to-Free-Cash-Flow Explanation
Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.
In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.
Be Aware
In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.
Thank you for viewing the detailed overview of Aravive's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.
Maria Carolina Petrini | officer: Chief Commercial Officer | RIVER OAKS TOWER, 3730 KIRBY DRIVE, SUITE 1200, HOUSTON TX 77098 |
Robert B. Geller | officer: Chief Medical Officer | RIVER OAKS TOWER, 3730 KIRBY DRIVE, SUITE 1200, HOUSTON TX 77098 |
Rudy Howard | officer: Chief Financial Officer | 322 WINDCHASE LANE, WILMINGTON NC 28409 |
Leonard Scott Dove | officer: Chief Operating Officer | RIVER OAKS TOWER, 3730 KIRBY DRIVE, SUITE 1200, HOUSTON TX 77098 |
Amato Giaccia | director, 10 percent owner | C/O VERSARTIS, INC., 1020 MARSH ROAD, MENLO PARK CA 94025 |
Gail Frances Mcintyre | officer: Chief Scientific Officer | C/O FURIEX PHARMACEUTICALS, INC., 3900 PARAMOUNT PARKWAY, SUITE 150, MORRISVILLE NC 27560 |
John Hohneker | director | C/O DIMENSION THERAPEUTICS, INC., 840 MEMORIAL DRIVE 4TH FLOOR, CAMBRIDGE MA 02139 |
Sigurd Kirk | director | 225 SUMMIT AVENUE, MONTVALE NJ 07645 |
Peter Tai-ching Ho | director | C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139 |
Vinay Shah | officer: Chief Financial Officer | C/O VERSARTIS, INC., 1020 MARSH ROAD, MENLO PARK CA 94025 |
Reshma Rangwala | officer: Chief Medical Officer | RIVER OAKS TOWER, 3730 KIRBY DRIVE, SUITE 1200, HOUSTON TX 77098 |
Michael W Rogers | director | C/O KERYX BIOPHARMACEUTICALS INC, ONE MARINA PARK DRIVE, BOSTON MA 02210 |
Eshelman Ventures, Llc | director | 319 N. 3RD STREET, SUITE 301, WILMINGTON NC 28401 |
Fredric N Eshelman | director | PPD INC, 929 NORTH FRONT STREET, WILMINGTON NC 28401 |
Rekha Hemrajani | director, officer: President and CEO | 3928 POINT EDEN WAY, HAYWARD CA 94545 |
From GuruFocus
By Value_Insider Value_Insider • 11-21-2022
By sperokesalga sperokesalga • 05-16-2023
By GuruFocusNews GuruFocusNews • 07-05-2022
By PRNewswire • 08-09-2023
By GuruFocusNews GuruFocusNews • 07-05-2022
By Value_Insider Value_Insider • 11-29-2022
By sperokesalga sperokesalga • 02-28-2023
By sperokesalga sperokesalga • 06-05-2023
By sperokesalga sperokesalga • 05-25-2023
By PurpleRose PurpleRose • 07-13-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.